Zoetis Inc (ZTS)
被低估基本面
72
价格
$69.94
市值
$29.52B
第一部分 · 这家公司值多少
概览
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$9.53B
最近12个月（截至2026/6/30）
净利润
$2.64B
最近12个月（截至2026/6/30）
自由现金流
$2.28B
股东权益合计
$3.42B
负债合计
$12.07B
流动比率
3.08
利息覆盖率
-
债务/EBITDA
2.27
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$112.17
当前价格
$69.94
安全边际
+37.7%
公允价值区间
$72.91 - $151.42
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
11.41
ROE
78.3%
市净率（P/B）
9.17
P/FCF
12.46
毛利率
71.7%
ROIC
-
盈利能力雷达图
价值创造（经济护城河）
ROIC
-
WACC
6.8%
ROIC − WACC
-
基本面分析标准
通过（18）
- EPS shows upward trend
- EPS CAGR 19.62%
- Gross Margin 71.7%
- P/FCF 12.46
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 69.3%
- Revenue Growth 5Y 7.2%
- Analyst Consensus 50% Buy
- PEG Ratio 0.93
- Earnings Quality (OCF/NI) 1.08
- Share Dilution -2.3%
- Net Margin Trend 27.7% vs 27.6%
- Piotroski F-Score 6/9
未通过（6）
- Price CAGR 3.15%
- P/B Ratio 9.17
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.5%
不可用（4）
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
Piotroski F-评分
信号混杂：部分领域需关注
盈利质量
高质量：盈利有现金流支撑
股权稀释
正在回购股份，对股东友好
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Ms. Kristin C. Peck | CEO & Director | 54 |
| Ms. Roxanne Lagano | Executive VP, General Counsel & Corporate Secretary | 60 |
| Mr. Wetteny N. Joseph CPA | Special Advisor to the CEO | 53 |
| Dr. Robert J. Polzer Ph.D. | Scientific Advisor | 56 |
| Mr. Jamie Brannan | Executive VP & Chief Commercial Officer | 52 |
| Mr. James K. Saccaro | Executive VP, CFO & COO | 52 |
| Mr. Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | 46 |
| Mr. Steven Frank | Vice President of Investor Relations | - |
| Ms. Julie A. Fuller | Executive VP, Chief Human Resources Officer & Global Operations | 52 |
| Mr. Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations | 37 |
审计风险
5
董事会风险
2
薪酬风险
6
股东权利风险
7
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for ZTS, sourced from Markets Gazette.
- 5/10/2026NEGATIVEZoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?
Zoetis Inc. was among the top large-cap decliners last week, experiencing a significant sell-off. This downturn was primarily attributed to weak earnings reports, cautious forward guidance from the company, and subsequent reductions in analyst price targets. The broader market sentiment also played a role, with declines seen across healthcare, software, networking, and industrial sectors. Investors are advised to monitor Zoetis's upcoming earnings calls and management commentary for signs of a potential turnaround or further headwinds.
via Markets Gazette